Business Wire - November 2, 2000
Under the agreement, Bristol-Myers Squibb and ViroLogic will sponsor a series of Continuing Medical Education programs for physicians on the topics of HIV therapy and drug resistance. The intent of the programs is to have prominent academic and community-based clinicians, along with distinguished researchers from industry, present the most up-to-date scientific and clinical data on resistance testing and its role in patient management.
"Physicians are increasingly turning to drug resistance testing to manage HIV infection," said Bill Young, Chairman and CEO of ViroLogic. "Our collaboration will help prepare physicians to take advantage of this important new technology - to anticipate and respond to drug resistance, avoid ineffective drugs, and in many cases improve patient outcomes."
As part of the agreement announced today, ViroLogic will also collaborate with Bristol-Myers Squibb on retrospective and prospective scientific studies on HIV therapy and resistance. The studies will employ ViroLogic's PhenoSense(TM) HIV resistance test and will include research on Bristol-Myers Squibb HIV drugs Videx(R) (didanosine) and Zerit(R) (stavudine).
About ViroLogic
ViroLogic is a biotechnology company developing and marketing innovative products to guide and improve treatment of viral diseases. The Company's proprietary technology, called PhenoSense(TM), tests for drug resistance and susceptibility in viruses that cause serious diseases such as AIDS, hepatitis B and hepatitis C.
ViroLogic's first product, PhenoSense HIV, is a test that directly and quantitatively measures resistance of a patient's HIV to antiviral drugs. The test results provide physicians with important information to help select appropriate drugs for their HIV patients. The Company is also developing PhenoSense products for other viral diseases and intends to use the results of its PhenoSense tests and other clinical data to develop its Therapy Guidance System(TM) (TGS(TM)), an interactive database to help physicians guide patient therapy.
Certain statements in this press release are forward-looking. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to, whether PhenoSense(TM) testing will achieve market acceptance, whether payers will authorize reimbursement for our products, whether we will be able to expand our sales and marketing capabilities, whether we encounter problems or delays in automating our process, whether we successfully introduce new products using our PhenoSense(TM) technology, whether intellectual property underlying our PhenoSense(TM) technology is adequate, whether we are able to build brand loyalty, and other risks and uncertainties detailed in our final Prospectus that is part of our Registration Statement on Form S-1, as declared effective by the SEC on May 1, 2000 (File No. 333-30896).
--30--MEM/ny*
CONTACT: ViroLogic Sidney Ho, Director of Public Affairs 650/635-1100, Ext. 7406 sho@virologic.com
001102
BW001101
Copyright © 2000 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .